Abstract There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (T reg ) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far with ex vivo expanded autologous T regs in type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with T reg infusion without immunomodulation regimens that promote stable donor T reg engraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for T reg generation, homeostasis, and function to promote long-term donor T reg persistence to provoke beneficial therapeutic outcomes.
Introduction
Solid organ transplantation is a well-established treatment for patients with end-stage organ failure. Advances in surgical techniques and development of immunosuppressive drugs targeted at T-cell responses responsible for graft destruction have been key in improving short-term outcomes. However, there still remains the risk of chronic rejection and in the case of pancreatic or islet transplantation for T1D patients, therapeutic success is curtailed by recurrence of autoimmunity, despite immunosuppression that prevents rejection [1] [2] [3] [4] [5] [6] . Moreover, chronic immunosuppression has significant toxicity and is associated with serious side effects, including increased susceptibility to infections. Therefore, there is a clear need to develop strategies for clinically applicable therapeutic protocols which are aimed at promoting tolerance induction that minimizes or eliminates long-term immunosuppression.
Immune tolerance is a state of unresponsiveness in the immune system. Self or natural tolerance is failure to attack the body's own proteins or other antigens. If the immune system attacks its own cells or tissues, an autoimmune disease could develop. Induced tolerance is lack of an immune response to external antigens that has been generated purposefully by modulating the immune system. This type of tolerance is important in cases of transplantation where the patients' immune cells Bsee^the allograft as foreign and mount an aggressive attack against it leading to graft rejection. Therapies in transplant setting are designed to target innate and/or adaptive immune responses that are thought to contribute to This article is part of the Topical Collection on Cellular Transplants graft rejection. Another approach to immunotherapy would involve promoting tolerance mechanisms through enhanced regulation of adaptive T-cell responses. Central T-cell tolerance occurs in thymus where T cells develop and mature through a process of T-cell receptor (TCR) recognition of Bself^antigens nestled in a major histocompatibility complex. Since high-affinity interaction could attack cells that display these self-peptides derived from body proteins, these T cells are eliminated through negative selection. Surviving thymic T cells leave and migrate throughout peripheral immune system (Fig. 1) .
A central issue of modern medicine is how peripheral selftolerance is achieved and preserved as increasing evidence has clearly demonstrated that potentially self-destructive T-cell clones can escape central tolerance and circulate in periphery of healthy individuals. There are several mechanisms for achieving peripheral tolerance, including anergy, negative selection occurring in the periphery, and control by regulatory T cells (T regs ) (Fig. 1) . In this review, we will summarize the T reg population and their use as adoptive T-cell therapy for tolerance induction strategies. This review will also focus on thymus-derived, natural T regs rather than induced regulatory T cells that are generated with TCR engagement and cytokines, since studies are demonstrating that natural T regs are more stable population and potent suppressors of Bself^and in preventing autoimmunity [7] [8] [9] . T reg -based immunotherapy could significantly impact development of new therapeutic protocols for transplant recipients and patients with autoimmunity based on administration of a T-cell population that could afford long-lasting protection from rejection and autoimmunity without the need for chronic immunosuppression. The first clinical trials with adoptive T reg therapy has occurred in graft-versus-host-disease (GVHD) prevention trials in bone marrow (BM) transplant recipients with promising results [10, 11] . However, T reg therapy could show promise in patients with autoimmunity, such as T1D, but pose more challenges due to the underlying autoimmune responses as well as in the context of allogeneic islet or pancreatic transplantation in these patients.
Adoptive T Regulatory Cell Therapy for Tolerance Induction
Adoptive immunity was first described by Billingham et al., in which studies showed transfer of primed immune cells could generate or Bpass^immunity in recipient mice [12] . Since this time, several animal studies have shown that T-cell adoptive transfer of immunity in settings of cancer, infection, and transplantation [13] [14] [15] [16] . T-cell adoptive therapy was then further extended in application by the use of IL-2 for ex vivo expansion of human T cells [17] [18] [19] [20] . The idea of suppressor T cells was first suggested by two rodent studies from Gershon and Kondo [21, 22] 
CD25
+ T regs and mice die within 1 month of birth. The identification of mutations in Foxp3 gene in scurfy mice and in Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome in humans, both of which succumb to lethal autoimmune disease early in life, was critical in establishing an essential role of T regs in the maintenance of peripheral self-tolerance. In mice, Foxp3 reduction and these cells suppress rejection of various allografts makes these cells highly attractive candidates for cell-based therapy for tolerance induction protocols in transplantation and autoimmune settings. Collectively, these experimental models suggest that T regs might be used in non-toxic approaches for preventing GVHD, allograft rejection, and restoring self-tolerance. However, the clinical application of adoptive T reg therapy is hindered by low T reg frequency resulting in a limited number of cells to inhibit desired immune responses, lack of stable engraftment of donor T reg inoculums, and the need for antigen specificity of T regs .
Adoptive T reg Therapy for Prevention of GVHD
There has been much success in T reg therapy to prevent GVHD [41] [42] [43] , which has led to the first clinical trials with T reg immunotherapy in BM transplant recipients [10, 11, 46 In the first clinical trial with T reg adoptive therapy, two patients after hematopoietic stem cell transplantation ( H S C T ) w i t h G V H D w e r e g i v e n e x p a n d e d CD4 + CD25 +
CD127
lo cells and showed these expanded T regs were safe and may have therapeutic benefit [57] . In a larger phase I/II trial, Brunstein et al. utilized T regs isolated from umbilical cord blood to lessen the possibility of expanding effector T-cell populations and found umbilical cord T regs were safe and reduced grade I/II GVHD [10] . In another phase I/II trial, heavily conditioned hematological malignant patients following HSCT received unexpanded T regs were found to enhance immune reconstitution, lower CMV reactivation incidence, and lower tumor relapse and GVHD [11] . This study showed immune regulation with human T regs and safety profile in these high-risk patients. Although these GVHD trials showed great promise, in solid organ transplantation or autoimmune settings will pose more challenges due to the fact that unmanipulated recipients may not respond to T reg therapy as successfully because of the large presence of alloreactive or auto-reactive T cells, respectively, leading to greater T reg numbers to achieve T reg /T eff ratios that will favor a regulatory environment. With results in from T reg trials in HSCT and T1D patients demonstrating that adoptive T reg therapy is well tolerated, a trial in solid organ transplantation is now under way, the ONE study. This study is an international, multi-center phase I/II trial that will test safety and production feasibility of several regulatory cell populations, including ex vivo expanded T regs , in living donor kidney transplant recipients. This trial aims at standardizing both experimental settings and endpoints and will likely allow collection of valuable data on the efficacy and safety of putative regulatory cell subsets for tolerance induction. In regards to T regs , this trial will compare expanded T regs from peripheral blood that is either polyclonal stimulated with anti-CD3 and anti-CD28 or alloantigen-driven with allogeneic antigen presenting cells (APC). Expansion protocol that utilizes stimulation with APCs, which enrich for allogeneic-specific T regs rather than expanding the entire T reg pool, could allow for a more potent T reg population for adoptive therapy [63] [64] [65] [66] . This type of expansion protocol is hindered by lack of sufficient time to expand recipients' T regs with donor APCs before transplant surgery. However, in the case of living-related kidney (or liver transplant) recipients, this approach is a more applicable strategy. Although the ONE trial is not designed to test the efficacy of the various regulatory populations, transplant patients will be immune monitored, which could provide valuable information on modulation of immune compartments following administration of regulatory cell populations and foster development of improved adoptive cell therapy for design of future clinical trials.
Clinical Trials in T1D and Solid Organ Transplantation

Key Requirements for Successful Adoptive T reg Immunotherapy
Although the development of ex vivo expansion T reg protocols have opened new avenues for adoptive T reg therapy in a clinical setting, there is still not much known about the in vivo environment necessary to support transferred donor T regs longterm. Indeed, an often overlooked hurdle that needs to be considered for successful T reg therapies that avoid the use of chronic immune suppression is to understand the host environment. Crucial factors required for T reg generation, homeostasis, and function must be incorporated in design of clinical trials based on T reg adoptive therapy, whether these T regs are expanded in vitro or infused after isolation for in vivo expansion.
Critical Barrier of Available Space and Minimizing Competition With Host T regs
As described above, mutations or alterations in Foxp3 or IL-2/ IL-2R interactions lead to immune compartments devoid of CD4 + CD25
+ T regs and mice die within 1-2 months from birth. Importantly, adoptive transfer of wild-type T regs into Foxp3-deficient mice prevents disease development in these models [73] , and our own studies in IL-2Rβ −/− mice showed T reg adoptive transfer leads to prevention of autoimmunity and tolerance to skin allografts with life-long donor T reg engraftment and suppressor function. Unlike normal mice that have a constant production of thymic T regs , a key feature of these mice is lack of continuous competition with endogenous T regs because of absent thymic production and peripheral maintenance of functional T regs resulting in a natural space for donor T regs to engraft and persist. Moreover, adoptive T reg transfer into these mice occurred shortly after birth when the neonatal environment is initially lymphopenic followed by gradual increase in lymphocytes until homeostatic numbers are obtained as lymphocytes develop and migrate to periphery. Neonatal IL-2Rβ −/− model demonstrates the importance of available peripheral space and lack of competition to long-term, stable donor T reg engraftment. When a similar adoptive transfer of T regs was performed in normal neonatal mice, there was 10-fold lower donor T reg engraftment compared to IL-2Rβ
, indicating that competition with endogenous T reg production did not allow significant donor engraftment. Several investigators have shown positive therapeutic outcomes when Ag-specific NOD T regs were adoptively transferred into NOD mice [68, 69] . However, these experimental approaches used recipient NOD mice that were devoid of either T or T reg cells, which results in natural space and lack of competition from endogenous T regs , which likely promoted donor T reg engraftment, resembling the IL-2Rβ −/− and Foxp3 −/− models.
In experimental transplantation models, successful adoptive T reg therapy was achieved in likewise immunocompromised recipients, including irradiated, athymic, T-cell depleted, or Rag −/− hosts [70] [71] [72] [73] [74] . Although long-term donor T reg engraftment was not examined in these studies, it is likely that the recipient lymphopenic environment promoted donor T reg engraftment due to the reduced competition from host immune cells. For example, ablative conditioning severely depletes lymphocytes, including cells in the primary and secondary immune tissues, and lymphocyte reconstitution is exceedingly delayed, which recapitulates the in vivo environment in adoptive transfer in neonatal Foxp3 −/− and IL-2Rβ
−/ − models. Collectively, these studies indicate that for successful T reg cell therapy, a critical obstacle that needs to be overcome is the competitive barrier created by the endogenous T regs . These observations have led to efforts in our laboratory to manipulate the T reg niche (Bspace^) and minimize competition with host T regs in wild-type mice with the goal of improving adoptive T reg immunotherapy. This critical requirement was confirmed in common laboratory mouse strains in the absence of genetic manipulations, specifically in studies of BM conditioning in non-autoimmune C57BL/6 and Balb/c strains [75] . Infused T regs engrafted, persisted long term, and contributed to tolerance induction to skin allografts. However, a possible concern in these studies was that infused donor T regs will not maintain their T reg phenotype; it has been shown that adoptive transfer of Foxp3 GFP+ T regs into lymphopenic hosts results in a large number of cells to become GFP-negative [76] [77] [78] . However, the loss of T reg phenotype was dampened when T regs were co-injected with CD4 + GFP-negative cells and Foxp3 loss emerges in the absence of IL-2 [76] . Despite initial lymphopenia induced by our BM conditioning, donor-positive CD4 T cells maintain Foxp3 expression in both mouse strains [75] . These data together with immuno-compromised strains revealed the importance of available Bspace^within the T reg niche and minimizing competition at the time of T reg infusion for long-term donor T reg persistence. These studies also exemplify the success in HSCT models in both experimental rodent model and in clinical trials in the prevention of GVHD.
Antigen Specificity of Adoptively Transferred T regs
Antigen has been shown to be another key requirement for T reg development and homeostasis. The ability of T regs to prevent thyroiditis was lost when thyroid had been ablated, but rats retained the ability to prevent autoimmune diabetes [79] , suggesting that the presence of antigen maintains a population of antigen-specific T regs . Moreover, T regs could be found within tolerant grafts, indicating that alloreactive T regs could potentially be recruited to or even retained at sites of alloantigen expression and actively participate in tolerance induction and/ or maintenance [80] [81] [82] [83] . Other studies showed constant presence of alloantigen was required to inhibit allogeneic responses and induce tolerance to allogeneic BM cells [70, 71] . We also have shown a specific enrichment of donor T regs to host alloantigen following adoptive transfer of allogeneic T regs into IL-2Rβ −/− mice, indicating T reg adoptive transfer allowed biological selection of donor inoculums resulting in therapeutic T regs capable of regulating autoimmunity and tolerance [40] . This dominant transplantation tolerance was towards the MHC antigens that the T regs were initially selected for. Collectively, these data have important implications in autoimmune settings. For example, in fully diabetic NOD (or T1D patients), insulin-specific or other islet-specific T regs may not engraft due to the loss of their cognate antigens. However, antigen-specific T regs could work in conjunction with antigen therapies, in prediabetic or recent onset diabetes where adequate β-cell mass still exists, or in islet transplant settings. Importantly, in transplant setting, allografts will act as the source of cognate antigen. Alternatively, allogeneic T regs from graft donors could be infused to potentially replenish these antigen-specific populations, but pose more of a challenge than recipients' antigen-specific T regs because of their immunogenicity. These types of strategies would involve adoptive transfer of antigen-specific T regs using protocols that favor their long-term engraftment through in vivo antigendriven selection and expansion for improved therapeutic efficacy. Furthermore, a major benefit from utilizing antigenspecific donor T regs is that these T regs will act only where antigen is present, thereby providing a local immunotherapy. Studies showed that T regs that are antigen-specific are more efficacious than polyclonal T regs at regulating autoimmune diabetes and responses to alloantigen [68, [83] [84] [85] . NOD mice are notoriously resistant to tolerance induction protocols [86] [87] [88] . Nonetheless, islet-specific T regs could have positive effects on diabetes prevention and diabetes remission in recent diabetic NOD mice. Islet-specific T regs were isolated from BDC2.5 NOD transgenic mice and were expanded ex vivo in the presence of IL-2 and then adoptively transferred to immuno-compromised NOD mice, including Rag −/− , Scid, or TCRα −/− NOD recipients together with either splenocytes from diabetic NOD mice or activated BDC2.5 effector T cells. Diabetes prevention was achieved with very low T reg /T eff ratio (1:160) and as few as 50,000-expanded BDC2.5 T regs [69] . However, when expanded BDC2.5 T regs were given to 13-week-old wild-type NOD, diabetes was prevented with 30-fold more T regs (1.5×10 6 ), while diabetes remission was achieved in only 36 % of recent diabetic NOD mice with two doses of 1.5×10 6 -expanded BDC2.5 T regs [89] . In another study by Bluestone's group, 60 % diabetes remission rates were achieved when 10 7 -expanded BDC2.5 T regs were given to recent onset NOD mice [68] . These studies show that antigen-specific T regs were efficacious compared to expanded NOD T regs ; however, success was achieved with low T reg numbers only when recipient mice had available Bspaceâ nd lack of competition with host T regs , indicating that similar success in autoimmune or transplant patients will require immunomodulation to recreate this in vivo environment to support their engraftment and therapeutic benefit.
In transplant setting, expansion of recipients' polyclonal T regs with allogeneic APC leads to alloantigen-specific T reg enrichment allowing more potent T reg population for immunotherapy [63] [64] [65] [66] lo T cells with allogeneic dendritic cells (DC). These activated T regs were readily expanded in vitro in the presence of allogeneic DC and IL-2, and in a humanized mouse model these enriched T regs could significantly reduce allogenic immune-mediated skin damage compared to polyclonal activated T regs [64] . In another study, Veerapathan et al. showed CD4
lo T cells that were stimulated with allogeneic DC in the presence of IL-2, IL-15, and rapamycin were enriched and occurred when alloantigen was presented directly or indirectly with autologous DC pulsed with allogeneic fibroblast lysates. Either population was more potent suppressors in vitro than polyclonal expanded or non-expanded T regs [66] . This group also demonstrated expansion of T regs against minor major histocompatibility antigens [65] . These studies show promise that alloreactive T regs can be selected and expanded and are more potent than polyclonal T regs in vitro, but failed to examine graft outcomes. Enriched allogeneic-specific T regs will be tested in the ONE clinical trial, and results will allow for development of improved clinical trials such that enriched donor-reactive T regs given after transplantation could lessen immunosuppression dosing and duration. Expanding donor-specific T regs would be possible when living related donors are used, but expansion may be cumbersome to implement from cadaveric organ donors. If T reg expansion protocols are shortened or if T regs could be administered days after transplantation, these would allow sufficient time for ex vivo T reg expansion and could overcome this hurdle for their therapeutic application in these types of transplant patients.
IL-2: Critical Factor for T reg Cell Development and Homeostasis
The expression of CD25 was the initial marker used to identify a population of T regs . Several studies, including our own, have proven that IL-2/IL-2R (IL-2 receptor) interaction represents an essential step in production and supports T reg homeostasis in steady state [67••, 90-97] (Fig. 2) . The role of IL-2 in T reg generation and maintenance has been extensively reviewed (see [98, 99] ). Here we will focus on the role of IL-2 in the context of T reg therapies. If significant long-term donor T reg engraftment will require immunomodulation prior to T reg infusion, it may be possible that other STAT5-dependent cytokines, such as IL-7 or IL-15, may act as homeostatic factor rather than IL-2 during these lymphopenic states. However, residual T reg compartment following ablation was also highly dependent on IL-2 and IL-7 acted more as a survival factor [100] . Moreover, IL-2 was also critical for the growth and survival of infused T regs following conditioning [75] . Despite low IL-2 in conditioned mice, levels are sufficient to drive substantial proliferation T reg compartment. This is likely due to T reg homeostasis requiring low IL-2 signaling [101] and their expression of high affinity IL-2Rs over other lymphocytes allows competitive advantage for IL-2 utilization. Impaired T reg function in NOD mice derives from low IL-2 levels in pancreas; proper IL-2 treatment restored T reg function and effectively reverses diabetes at onset in a fraction of mice by augmenting the T reg /T eff ratio [102] . Furthermore, enhanced β-cell destruction occurs by Th1 and Th17 CD4 + T subsets in recent diabetic mice, but low-dose IL-2 administration downregulated production of these cytokines [102] . In contrast, high-dose IL-2 triggered disease likely by promoting autoreactive T cells.
IL-2 continues to be used in cancer immunotherapy at high doses to boost tumor responses, but has had limited use in autoimmune setting due to the potential risks of stimulating effector T cells (for review, see [13, 103] ). In phase I/II pilot study combining DCs and IL-2 in metastatic renal cancer patients, a specific anti-tumor response was detected, but a transient and massive increase of circulating T regs was also observed [104] . A phase 1 clinical trial in recent onset T1D with a combination therapy of IL-2 and rapamycin was recently completed [105] . Although there was expansion of T regs , there was proliferation of T eff and NK cells and a worsening of metabolic function. It appears that the IL-2 dose was not Fig. 2 Role of IL-2 for T reg development and homeostasis. The essential role for IL-2 resides at the earliest stages of the production of T regs in thymus. The IL-2/IL-2R interaction is active in thymus at the earliest stage of T reg development to promote T reg expansion and to upregulate Foxp3 and CD25 to normal levels. These T regs exit the thymus and home to neonatal lymph nodes where IL-2 acts as a potent growth factor promoting substantial T reg expansion. In the adult peripheral compartment, IL-2 remains the dominant mechanism for T reg homeostasis, but mature T regs can be maintained low-dose IL-2. In lymphopenic conditions, IL-2 is still the dominant cytokine controlling T reg homeostasis and maintaining high expression of CD25 and Foxp3. IL-7 acts as a survival factor to maintain T regs in the periphery, whether during the steady state, lymphopenia, or following T reg infusion following ablation sufficiently low to achieve only specific effects on T regs. In an autoimmune-related HCV-induced vasculitis clinical trial with low-dose IL-2, it showed specific T reg activation without stimulating other T cells and showed a good safety profile. Importantly, low-dose IL-2 results in increased T reg /T eff ratio favoring regulation, downregulates inflammation, and failed to lead to viral reactivation in these patients [106] . This group also recently reported that phase I/II study in T1D patients with low-dose IL-2 was well tolerated and IL-2 induced a dosedependent increase in proportion of T regs [107] . These clinical trials with IL-2 have important implications in developing T reg immunotherapy for the clinical setting in that the proper lowdose IL-2 combined with T r e g infusion following immunomodulation may allow for far fewer numbers of donor T regs for positive therapeutic outcomes and dampen the inflammatory environment in solid organ transplantation and in autoimmunity.
CD8 T Regulatory Cells: Potential Cellular Source for Adoptive T reg Therapy
+ cells have been the main cell population to date that has been tested in clinical trials. As mentioned above, the ONE trial will examine several other regulatory populations to be potentially used for therapeutic benefit. However, Harvey Cantor's group have identified an IL-15-dependent, Qa-1-restricted CD8 T cell with regulatory properties that has been shown to be essential in maintenance of self-tolerance and prevention of autoimmune disease in mice [108] [109] [110] [111] . These cells can be identified and purified on the expression of the surface markers CD44
These cells could also be expanded ex vivo driven by peptide and infusion of these peptide-specific CD8 T regs strongly inhibits collagen-induced arthritis mouse model by eliminating pathogenic T follicular helper and Th17 cells [111] . This group has recently identified the human counterpart to these murine CD8 T regs . These human CD8 T regs express KIR2DL2/3 or KIRDL1 along with expression of CD44 and CD122, and IL-15 promotes their activation and proliferation [112] . These cells could represent another regulatory population that could be considered in future adoptive T reg therapy given that these cells can be purified, expanded ex vivo, and can be antigen specific.
Concluding Remarks
Promoting immune regulation through enhancing T regs offers the hope to suppress many unwanted immune responses in transplantation to prevent graft rejection, as well as a plethora of autoimmune diseases and GVHD. However, results in animal models and in recent clinical trials with adoptive T reg therapy are highlighting the need to consider the in vivo environment to support their engraftment, persistence, and function of infused T regs for the future design of clinic trials in solid organ transplantation. Success in both experimental models and in clinical trials required immunomodulation to recapitulate a supportive T reg environment. T reg immunotherapy in autoimmune settings will pose more challenges given chronic inflammation could create a non-supportive environment for T regs . However, the use of low-dose IL-2 could possible overcome the inflammatory environment and foster regulation over effector responses and promote a supportive environment for stable engraftment of infused donor T regs . The transplantation setting could provide an adequate source of cognate antigen to drive antigen-specific regulation through selection and expansion and in context of autoimmunity where self- Fig. 3 In vivo environment for T reg Immunotherapy. To recapitulate the in vivo environment to promote stable T reg engraftment will require immunomodulation prior to T reg infusion. This immunomodulation needs to create initial space and minimize competition with rebounding host T regs to promote donor T regs to engraft and persist. The addition of low-dose IL-2 for homeostatic support for the Treg compartment, which will be composed of both recipient and donor T regs , will foster T reg numbers, but may also play a role in stabilizing T reg signature and downregulate inflammation antigens are lost from immune destruction. Collectively, successful T reg immunotherapy will likely require combinational approaches in which T reg infusion occurs following immunomodulation to make space in recipient's T reg compartment and to minimize competition with host T regs accompanied with low-dose IL-2 to provide homeostatic support for T reg compartment for long-term persistence of donor T regs (Fig. 3) . However, introduction of immunomodulation could potentially have unwanted side effects that would need to be evaluated for combinational approaches. For example, the use of anti-thymoglobulin (ATG) in induction protocols leads to dramatic lymphocyte depletion and is associated with T reg expansion in vivo favoring a shift in T reg /T eff ratio. However, CD4 and CD8 memory T cells were resistant to ATG depletion and were found to expand following treatment [113, 114] . Recently, T regs have been shown to play a critical role in natural killer (NK) cell homeostasis, activation, and function, predominantly by controlling the availability of IL-2 in the microenvironment [115] [116] [117] . In T reg absence, NKs produce abundant IFNγ and contribute to diabetic lesion in NOD mice and NKs were found to be initiators of autoimmune response by promoting CD4 T cells. In conclusion, future studies aimed at directly examining these issues in the context of clinically relevant approaches which could afford therapeutic synergy and considerably reduce the need for large numbers of T regs for therapy will provide the framework for development of novel strategies for tolerance induction. 
